Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up

Overview

Journal Intern Med

Specialty General Medicine

Date 2021 Jan 18

PMID 33456036

Citations 1

Authors

Tomoko Tadokoro

Koji Fujita

Kei Takuma

Mai Nakahara

Kyoko Oura

Shima Mimura

Teppei Sakamoto

Takako Nomura

Joji Tani

Asahiro Morishita

Hirohito Yoneyama

Hideki Kobara

Takashi Himoto

Tsutomu Masaki

Affiliations

Soon will be listed here.

Abstract

We treated a 51-year-old Japanese man with chronic hepatitis B (viral load 7.6 LC/mL, genotype C). Hepatitis B virus DNA and HBe antigen were undetectable during the administration of the nucleic acid analogs (NUCs) lamivudine and adefovir, although the concentration of HBs antigen (HBsAg) was 851.2 IU/mL. The HBsAg levels were reduced 150-fold when pegylated-interferon (Peg-IFN) α-2a was administered weekly for 48 weeks and did not increase during the rest period. Therefore, Peg-IFNα-2a was administered twice each week. During this time, HBsAg reached undetectable concentrations, and HBs antibody was detected and continued to be detectable during the three-year follow-up. These unprecedented findings suggest that IFN may contribute to the seroclearance of HBsAg in patients treated with NUCs.

Citing Articles

Clinical Efficacy of PEG-IFN-2a and PEG-IFN-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study.

Jia N, Gao W, Fan X, Gao H, Li X, Mi B Oxid Med Cell Longev. 2022; 2022:3185320.

PMID: 35726331 PMC: 9206564. DOI: 10.1155/2022/3185320.

References

Yuen M, Wong D, Fung J, Ip P, But D, Hung I . HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135(4):1192-9. DOI: 10.1053/j.gastro.2008.07.008. View

Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T . Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int J Mol Sci. 2018; 19(7). PMC: 6073286. DOI: 10.3390/ijms19071940. View

Liu G, Huang X, Shen S, Hu W, Peng B . Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatol Res. 2015; 46(1):100-10. DOI: 10.1111/hepr.12584. View

Piratvisuth T, Marcellin P, Popescu M, Kapprell H, Rothe V, Lu Z . Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2011; 7(2):429-36. DOI: 10.1007/s12072-011-9280-0. View

Tseng T, Liu C, Yang H, Su T, Wang C, Chen C . High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012; 142(5):1140-1149.e3. DOI: 10.1053/j.gastro.2012.02.007. View

Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E . Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2016; 67(2):362-371. PMC: 5868296. DOI: 10.1136/gutjnl-2016-312653. View

Chen C, Yang H, Su J, Jen C, You S, Lu S . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73. DOI: 10.1001/jama.295.1.65. View

Zhou Y, Zhang Z, Zhao Y, Wu L, Li B . Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis. World J Surg. 2014; 38(9):2395-402. DOI: 10.1007/s00268-014-2586-z. View

Yin J, Li N, Han Y, Xue J, Deng Y, Shi J . Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31(29):3647-55. DOI: 10.1200/JCO.2012.48.5896. View

10.

Sakamoto K, Beppu T, Hayashi H, Nakagawa S, Okabe H, Nitta H . Antiviral therapy and long-term outcome for hepatitis B virus-related hepatocellular carcinoma after curative liver resection in a Japanese cohort. Anticancer Res. 2015; 35(3):1647-55. View

11.

Giannakopoulos N, Luo J, Papov V, Zou W, Lenschow D, Jacobs B . Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun. 2005; 336(2):496-506. DOI: 10.1016/j.bbrc.2005.08.132. View

12.

Simonetti J, Bulkow L, McMahon B, Homan C, Snowball M, Negus S . Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010; 51(5):1531-7. DOI: 10.1002/hep.23464. View

13.

Brunetto M, Moriconi F, Bonino F, Lau G, Farci P, Yurdaydin C . Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009; 49(4):1141-50. DOI: 10.1002/hep.22760. View

14.

. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014; 44 Suppl S1:1-58. DOI: 10.1111/hepr.12269. View